SCHAUMBURG, Ill., March 31, 2014 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Adenosine Injection, USP, a pharmacologic stress agent, in two preservative- free vial presentations. According to IMS, for the 12 months ending January 2014, the US market for Adenosine Injection, USP approximated $43 million. As with all products in Sagent's portfolio, Adenosine features the company's PreventIV Measures SM packaging and labeling, designed to help reduce medication errors. "We are pleased to be working with our joint venture partner, Agila, a Mylan company, to support the launch of Adenosine at market formation," said Jeffrey M. Yordon, Chief Executive Officer and Chairman of the Board of Sagent. About Adenosine Injection, USP Adenosine Injection, USP is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. The package insert, available at www.sagentpharma.com , contains the indications, complete side effect profile, and prescribing information. About Sagent Pharmaceuticals, Inc. Sagent Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.
CONTACT: INVESTOR CONTACT: Jonathon Singer, Sagent 847-908-1605 email@example.com